Convergent mechanisms underlying rapid antidepressant action

P Zanos, SM Thompson, RS Duman, CA Zarate… - CNS drugs, 2018 - Springer
Traditional pharmacological treatments for depression have a delayed therapeutic onset,
ranging from several weeks to months, and there is a high percentage of individuals who …

Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors

CW Lindsley, KA Emmitte, CR Hopkins… - Chemical …, 2016 - ACS Publications
Allosteric modulation of GPCRs has initiated a new era of basic and translational discovery,
filled with therapeutic promise yet fraught with caveats. Allosteric ligands stabilize unique …

(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions

P Zanos, JN Highland, BW Stewart, P Georgiou… - Proceedings of the …, 2019 - pnas.org
Currently approved antidepressant drugs often take months to take full effect, and∼ 30% of
depressed patients remain treatment resistant. In contrast, ketamine, when administered as …

The antidepressant effects of an mGlu2/3 receptor antagonist and ketamine require AMPA receptor stimulation in the mPFC and subsequent activation of the 5-HT …

K Fukumoto, M Iijima, S Chaki - Neuropsychopharmacology, 2016 - nature.com
We have reported the antidepressant effects of both metabotropic glutamate 2/3 (mGlu2/3)
receptor antagonists and ketamine in several animal models, and proposed that …

Molecular pharmacology and neurobiology of rapid-acting antidepressants

TD Gould, CA Zarate Jr… - Annual review of …, 2019 - annualreviews.org
For decades, symptoms of depression have been treated primarily with medications that
directly target the monoaminergic brain systems, which typically take weeks to exert …

Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders

S Dogra, PJ Conn - Neuropharmacology, 2021 - Elsevier
The discovery of robust antidepressant effects of ketamine in refractory patients has led to
increasing focus on agents targeting glutamatergic signaling as potential novel …

Rapid and sustained antidepressant action of the mGlu2/3 receptor antagonist MGS0039 in the social defeat stress model: comparison with ketamine

C Dong, J Zhang, W Yao, Q Ren, M Ma… - International Journal …, 2017 - academic.oup.com
Background: Similar to the N-methyl-D-aspartate receptor antagonist ketamine, the
metabotropic glutamate 2/3 receptor antagonist, MGS0039, shows antidepressant effects …

[HTML][HTML] The mechanisms underlying montelukast's neuropsychiatric effects-new insights from a combined metabolic and multiomics approach

CF Marques, MM Marques, GC Justino - Life sciences, 2022 - Elsevier
Aims Montelukast (MTK) is an antagonist of the cysteinyl leukotrienes receptor 1 widely used
to manage asthma symptoms among adults and children. However, it has been associated …

(S)-norketamine and (2S, 6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression

R Yokoyama, M Higuchi, W Tanabe, S Tsukada… - Pharmacology …, 2020 - Elsevier
Clinical and preclinical studies have shown that the N-methyl-d-aspartate receptor
antagonist ketamine exerts rapid and long-lasting antidepressant effects. Although ketamine …

Agmatine, by improving neuroplasticity markers and inducing Nrf2, prevents corticosterone-induced depressive-like behavior in mice

AE Freitas, J Egea, I Buendia, V Gómez-Rangel… - Molecular …, 2016 - Springer
Agmatine, an endogenous neuromodulator, is a potential candidate to constitute an
adjuvant/monotherapy for the management of depression. A recent study by our group …